Commercial CRO & CDMO services

What is the commercial stage of drug development?

Commercial begins once a drug has an approval, or is close enough that a sponsor has to commit to launch supply. Everything before it (discovery, preclinical, the IND, the clinical program, even the validation batches in CMC) was about proving the molecule works and can be made. Commercial is about making it, releasing it, and getting it to patients month after month, at volumes the clinical batches never saw, without a stockout and without a quality event that pulls product off the shelf.

The work splits into a few buckets a sponsor tends to source as a group. Commercial manufacturing runs the validated process at full scale on a recurring schedule. Supply chain and logistics moves drug substance, drug product, and finished goods through a cold or controlled chain to distributors and pharmacies. Lifecycle management keeps the product compliant and competitive after launch: post-approval changes, second-source qualification, cost-down work, line extensions, and eventual generic or biosimilar defense. Two functions sit over all of it and never stop. CMC regulatory files and maintains the approved process with FDA, EMA, and other agencies. GxP quality and compliance runs the system that keeps every batch inspection-ready.

The economics flip here too. In development you spend to reduce risk. At commercial you spend to protect revenue and margin, so cost of goods, second sourcing, and supply resilience start to matter as much as the science. A single sole-source site with no qualified backup is a real business risk, which is why second-source qualification and technology transfer come up so often in commercial sourcing.

What CRO and CDMO services are included in commercial manufacturing and supply?

Most commercial work sits on the CDMO side, since it is physical manufacturing and supply, with CRO and consulting partners layered in for regulatory and quality. Here is what buyers actually source under each category.

• Commercial manufacturing: GMP production of drug substance (small molecule API, biologics, cell and gene therapy, ADC, peptide, mRNA) and drug product at commercial scale, including aseptic fill-finish, packaging and labeling, serialization, and routine batch release. This is the recurring engine, run to a forecast, with capacity for large biologics reserved well in advance.
• Supply chain and logistics: demand and supply planning, cold-chain and controlled-room-temperature distribution, customs and import-export, serialization and track-and-trace (DSCSA in the US, EU FMD in Europe), 3PL warehousing, and returns and reverse logistics. For cell and gene therapy this extends to vein-to-vein chain-of-identity and chain-of-custody handling.
• Lifecycle management: post-approval change management, second-source and dual-source qualification, process improvement and cost-of-goods reduction, scale-up to an additional site, line extensions and new presentations (new strengths, devices, or pediatric formulations), and managing the product through loss of exclusivity.
• CMC regulatory: authoring and filing the commercial CMC dossier (Module 3), managing post-approval supplements and variations (PAS, CBE-30, CBE-0, EU Type IA/IB/II), annual reports, comparability protocols, and keeping the approved process aligned across every market where the drug is sold.
• Quality and compliance (GxP): the commercial quality management system, batch disposition by a quality unit or Qualified Person, deviation and CAPA handling, change control, supplier and supplier qualification audits, stability program management, complaint handling, recall readiness, and inspection support for FDA, EMA, and other regulators.
• Tech transfer and stability: moving a validated process into a new or backup site (process validation, PPQ batches, comparability), plus ongoing commercial stability studies that support the approved shelf life and any extensions.

How do you choose a commercial CDMO?

Picking a commercial partner is a higher-stakes call than choosing a discovery or preclinical CRO, because you are locking in the relationship that supplies your revenue. A wrong choice shows up as a launch delay, a stockout, or a warning letter, not just a slipped study. A few things drive the decision more than price.

• Inspection and regulatory track record: ask for the site's recent FDA and EMA inspection history, Form 483 observations and how they were closed, and whether it holds approvals. A validated, commercially approved site for your modality is worth more than a cheaper unproven one, and a clean Pre-Approval Inspection history is a strong signal.
• Modality and scale fit: a site that runs commercial monoclonal antibodies is not automatically right for a viral vector, an ADC, or an autologous cell therapy. Confirm the supplier has commercial-scale equipment and suites and a real commercial track record for your exact modality, not just clinical batches.
• Capacity and reservation terms: large-molecule capacity is constrained and booked ahead. Understand reserved capacity, minimum order quantities, take-or-pay commitments, and how the supplier absorbs your demand swings.
• Supply resilience and second sourcing: single-source risk is the quiet killer of a launch. The stronger answer is usually a primary plus a qualified backup site, so ask early how tech transfer to a second source would work and what it costs.
• Quality-system maturity and tech-transfer experience: you want a supplier that has received many transfers and runs a quality system that will pass your own audit. The on-site quality audit decides this, not the sales deck.
• Total cost of goods, not unit price: yield, batch size, change-over time, and shipping move COGS more than the headline price per gram or per vial. Model the landed, released cost across a few years of forecast, not a single batch.

How long does it take to stand up commercial supply?

Commercial engagements are long-horizon by nature. A discovery study you scope in weeks; a commercial supply agreement is a multi-year relationship, and the lead time to stand it up is measured in quarters.

Technology transfer into a new commercial site commonly runs many months to over a year for a biologic, because it includes engineering runs, process performance qualification (typically three consecutive PPQ batches), analytical method transfer, and the regulatory filing to add or change the site. Small molecules move faster than biologics. Cell and gene therapies move slower and are more bespoke. Aseptic fill-finish adds media fills and re-qualification on top.

Capacity for in-demand biologics is often reserved one to two years before you need the slots, so sponsors approaching approval start these conversations during late-phase clinical, not after the agency decision. Post-approval changes carry their own clocks: some are immediate (CBE-0), some need a 30-day notice (CBE-30), and a prior approval supplement can take many months of agency review before you can ship product made the new way.

One practical sequencing point: teams that need a backup supplier usually begin second-source qualification well before the primary is strained. Qualifying a new site after you already have a supply gap is the worst possible time to start.

What quality and compliance requirements apply to commercial manufacturing?

At commercial, GMP is not a milestone you pass once. It is the baseline state your supply lives in every single day. GxP is the umbrella over the good-practice regulations: GMP (manufacturing) dominates here, GDP (distribution practice) governs how product moves and is stored, and GLP and GCP are largely behind you by this stage (they belonged to preclinical safety and clinical conduct).

Every commercial batch is released under a quality system. A quality unit (or Qualified Person in the EU) dispositions each lot, deviations and out-of-specification results are investigated and closed with CAPAs, changes go through formal change control, and the full paper or electronic trail has to survive an inspection that can arrive with little notice. Data integrity (the ALCOA+ principles) is a frequent focus of modern FDA and EMA inspections, so the supplier's electronic records and audit trails matter as much as the physical process.

For the sponsor, two quality realities are non-negotiable. First, you remain accountable for product made on your behalf, so a Quality Agreement that spells out who owns which decision (release, deviations, recalls, regulatory reporting) is a core deliverable, not boilerplate. Second, your own quality team has to audit and qualify the supplier's site before the first commercial batch and on a recurring basis after. The supplier's GMP certificates and inspection history are the screen; your audit is the decision.

How does sourcing commercial services through BioBridgeX work?

BioBridgeX is a neutral marketplace for outsourced drug development, covering every stage from discovery through commercial, across all indications and modalities. We are not a CDMO and we do not steer you to a house favorite. You tell us the molecule, modality, scale, and timeline; we match you with qualified suppliers for the commercial categories you need; and you compare them side by side.

For buyers it is free. There is no charge to search, get matched, or compare quotes. Suppliers pay a flat 2% fee on work transacted through the platform, and that is the whole model, which is what keeps the matching honest.

The real advantage at the commercial stage is the contracting. A working commercial supply chain almost always means more than one supplier: a drug substance maker, a fill-finish site, a packager, a 3PL, often a CMC regulatory consultant and a quality partner. Sourced the usual way, that is a stack of separate master agreements, POs, and invoices to negotiate and reconcile. Through BioBridgeX you contract once. BioBridgeX acts as the neutral marketplace, so you compare quotes and contract directly with every supplier in the engagement, in one place, while each specialist still does its own work. That collapses the legal and procurement overhead that normally makes multi-supplier commercial sourcing slow.

You stay in control of the choice. We surface qualified options with the signals that matter at commercial (modality fit, scale, compliance attributes, region), and you decide. When you are ready, the contracting and a single point of accountability are handled for you.